API | bilastine

bilastine Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG PubChem repoDB

Active Ingredient History

NOW

Bilastine, sold under the brand name Ilaxten among others, is a second-generation antihistamine medication which is used in the treatment of allergic rhinoconjunctivitis and urticaria (hives). ^Wikipedia

Chemistry

SMILES: CCOCCn1c(nc2ccccc12)C3CCN(CCc4ccc(cc4)C(C)(C)C(=O)O)CC3
InChIKey: ACCMWZWAEFYUGZ-UHFFFAOYSA-N
Mol. Mass: 463.62
ALogP: 4.86 Partition coefficient
ChEMBL Molecule:
bilastine

More Chemistry

Pharmacology

Mechanism of Action:
- Histamine H1 receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bellozal | bilastine | bilaxten | f-96221-bm1 | ilaxten

Organizations (31)

Research & Development (31)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Asthma (Phase 4)

Chronic Urticaria (Phase 3)

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic (Phase 3)

Healthy Volunteers (Phase 1)

Hypersensitivity (Phase 2)

Pharmacokinetics (Phase 1)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 4)

Urticaria (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 23
# of Trial Organizations: 31

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue